经导管动脉栓塞治疗胰腺腺癌相关胃肠道出血:临床疗效与临床结局预测因素
这项2001—2017年的回顾性研究纳入58例因胰腺腺癌相关胃肠道出血接受经导管动脉栓塞(TAE)的患者,技术成功率98%,首次和总体临床成功率分别为79%和88%,30天死亡率为22%;支架相关出血并不少见(22例)且临床成功率相当(82%),大量输血和TNM 4期与临床失败相关。
要点
- 血管造影示出血灶47例(81%),其余11例见肿瘤染色。
- 支架相关出血22例,可见动脉截断(13/22)和动脉胆管瘘(5/22)。
- 大量输血和TNM 4期与临床失败相关(P=0.035和0.038)。
核心结论
- TAE对胰腺腺癌相关胃肠道出血有效且安全。
- 支架相关出血并不少见,且伴可经TAE处理的血管异常。
- 大量输血和TNM 4期与临床失败相关。
研究设计与样本
- 回顾性研究,2001—2017年纳入58例因胰腺腺癌相关胃肠道出血接受TAE的患者。
- 评估TAE的技术成功与临床成功、患者特征与栓塞细节等临床因素、并发症及30天死亡率。
- 采用单因素分析确定与临床结局相关的因素。
关键影像表现/征象
- 血管造影检出出血灶47例(81%),其余11例表现为肿瘤染色。
- 支架相关出血22例,特征性血管造影表现包括动脉截断(13/22)和动脉胆管瘘(5/22)。
- TAE相关并发症2例,为缺血性肝炎和小肠梗死。
- 首次血管造影显示肠系膜上动脉出血3例。
诊断标准与关键数值
- 技术成功率为98%,首次和总体临床成功率分别为79%和88%。
- N-丁基氰基丙烯酸酯(NBCA)为最常用栓塞剂(53%)。
- 支架相关出血的临床成功率为82%。
- 总体30天死亡率为22%。
- 单因素分析显示大量输血和TNM 4期与临床失败相关(P=0.035和0.038)。
临床应用与阅片要点
- 血管造影时除寻找出血灶外,应注意肿瘤染色这一间接征象。
- 对支架相关出血,需识别动脉截断和动脉胆管瘘等血管异常,此类病变适于TAE。
- 肠系膜上动脉出血及发生并发症(缺血性肝炎、小肠梗死)的患者均与30天死亡相关,阅片和报告中应关注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the clinical efficacy of transcatheter arterial embolization (TAE) for managing pancreatic adenocarcinoma-related gastrointestinal (GI) bleeding, and to determine the factors associated with clinical outcomes.
METHOD: From 2001-2017, this retrospective study included 58 patients who underwent TAE for pancreatic adenocarcinoma-related GI bleeding. The technical and clinical success of TAE, clinical factors including patient characteristics and embolization details, complications, and the 30-day mortality were evaluated. Univariate analyses were performed to determine the factors related to the clinical outcomes.
RESULTS: On angiography, bleeding foci were detected in 47 patients (81%), while the other 11 patients showed tumor staining. Technical success rate was 98%, and first session and overall clinical success rates were 79% and 88%, respectively. N-butyl cyanoacrylate (NBCA) was the most commonly used embolic agent (53%). Stent-related bleeding was shown in 22 patients with characteristic angiogram such as arterial cut-off (13/22) and arteriobiliary fistula (5/22), with comparable clinical success rate (82%). Bleeding from the superior mesenteric artery (n = 3) at the first session of angiography and complications (n = 2), such as ischemic hepatitis and small bowel infarction, were all associated with a 30-day mortality. The overall 30-day mortality rate was 22%. Univariate analysis showed that massive transfusion and TNM stage 4 were related to clinical failure (P = 0.035 and 0.038, respectively).
CONCLUSIONS: TAE was effective and safe for pancreatic adenocarcinoma-related GI bleeding. Stent-related bleeding was not uncommon, and associated with vascular abnormality amenable to TAE. Massive transfusion and TNM stage 4 were related to clinical failure.
引用
- Lee SM, Jeong SY, Shin JH, et al. Transcatheter arterial embolization for gastrointestinal bleeding related to pancreatic adenocarcinoma: clinical efficacy and predictors of clinical outcome. Eur J Radiol. 2019. PMID: 31877509. doi:10.1016/j.ejrad.2019.108787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。